THE OFFICIAL NEWS SOURCE OF ACR CONVERGENCE 2022 • NOVEMBER 10-14



Johan Dalén: Cost consequences in inflammatory arthritis

Poster presenter: Johan Dalén, lead consultant, real world evidence strategy and analytics, commercialization and outcomes, ICON

Poster title: Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach

Scheduled poster session day and time: Friday, Nov. 6, 9 – 11 a.m.

Visit the Poster Hall

In general, what is your poster about?

A study of the cost consequences of non-persistence in the treatment with subcutaneous tumor necrosis factor-alpha inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis (collectively inflammatory arthritis).

Why did you decide to investigate this topic?

Improved understanding of cost consequences of non-persistence adds a perspective to payers making reimbursement decision. 

What are you working on next related to this poster?

A study utilizing conditional inference decision tree methods to identify predictors of treatment persistence with subcutaneous tumor necrosis factor-alpha inhibitors in inflammatory arthritis.

What excites you most about your work?

The use of population-based data minimizes the risk of selection bias, and therefore presents estimates of cost consequences with high validity.